Tepmetko (Tepotinib) for Lung Cancer

Overview
Tepmetko is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with metastatic non-small cell lung cancer (NSCLC) who have MET exon 14 skipping alterations, as confirmed by a test. Tepmetko is also known by its drug name, tepotinib.

Tepmetko is a kinase inhibitor. It works by blocking specific proteins, known as kinases, that promote the growth of cancer cells. By inhibiting these kinases, Tepmetko helps slow or stop the growth of lung cancer tumors.

How do I take it?
Prescribing information states that Tepmetko is taken orally in tablet form. The recommended dosing schedule is once daily with food. The treatment should be continued until there is disease progression or side effects become intolerable. Tepmetko should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Tepmetko include edema (swelling), nausea, fatigue, musculoskeletal pain, diarrhea, dyspnea (difficulty breathing), decreased appetite, and rash. Laboratory abnormalities such as decreased lymphocytes (a type of white blood cell), decreased albumin (a protein in the blood), decreased sodium, increased gamma-glutamyltransferase (a liver enzyme), increased amylase, increased lipase, increased ALT (alanine aminotransferase), increased AST (aspartate aminotransferase), and decreased hemoglobin may also occur.

Rare but serious side effects may include interstitial lung disease (lung inflammation), hepatotoxicity (liver damage), pancreatic toxicity, and embryo-fetal toxicity (damage to an embryo, fetus, or unborn baby). 

For more information about this treatment, visit:
Label — Tepmetko — Tepotinib Hydrochloride Tablet — DailyMed

Tepmetko — Drugs.com